OUR GROUP OUR HEALTHCARE OFFERING OUR AREAS OF EXPERTISE OUR COMMITMENTS NEWSROOM CAREERS PARTNERING PRESS FR MEDIATOR INFORMATION The Servier Group Committed to therapeutic progress to serve patient needs Meet the healthcare challenges of tomorrow Our news NEWS Servier invests 100 million euros in a new production unit at its Oril Industrie site 11 / 25 / 2021 NEWS Immuno-oncology: Servier and Aqemia cooperate on AI and quantum physics-driven drug discovery 12 / 03 / 2021 NEWS Servier joins the Act4Nature International Initiative 12 / 01 / 2021 22500 employees 150 countries in which the Group’s medicines are distributed 23 % of revenue from brand-name medicines invested in R&D in 2019/2020. € 4.7 billion euros in revenue in 2019/2020 comprising €3.3 billion for brand-name medicines and €1.4 billion for generic medicines. 4 therapeutic areas oncology, cardiometabolism, neuroscience and immuno-inflammation The basis for our actions Because passing on to future generations a world that can ensure access to quality health care for all is our vision for the future, at Servier, all over the world, we are ready to meet the health care challenges of tomorrow, for and with patients. Discover our corporate video. Sorry, your browser doesn't support embedded videos. TERMS OF USEDATA PRIVACYCOOKIE MANAGEMENTCONTACT USREPORT A SIDE EFFECT ©2020 SERVIER LABORATORIES